Burkitt lymphoma

This early-stage trial is testing an investigational therapy called B019, which uses a patient's own immune cells engineered to recognize and attack leukemia cells. The study focuses on people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard…

This trial is testing an experimental therapy called CD22 CAR T cells in adults with certain types of B cell lymphomas that have come back or not responded to previous treatments. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack…

This large trial is testing whether adding the targeted drugs blinatumomab or venetoclax to standard chemotherapy can improve survival and reduce side effects in children with intermediate- or high-risk B-cell acute lymphoblastic leukemia (ALL). The study compares different sched…

This study tests a drug called IgPro20 in 63 adults who have a weakened immune system after receiving CAR T-cell therapy for blood cancers like lymphoma or multiple myeloma. The goal is to see if the drug can lower the number of serious bacterial infections, such as pneumonia or …

This study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…

This phase 2 trial is testing a combination of blinatumomab (an immune-boosting drug) with dasatinib or imatinib (targeted pills) and standard chemotherapy for people with a specific type of leukemia called Philadelphia chromosome-positive or Philadelphia chromosome-like B-ALL. T…

This study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…

This study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…

This study tests a drug called zilovertamab vedotin in children and young adults whose blood cancers (like certain leukemias and lymphomas) or solid tumors (neuroblastoma, Ewing sarcoma) have come back or not responded to treatment. The goal is to see if the drug is safe and can …

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…

This early-phase trial is testing a new CAR T-cell therapy called AUTO1 (obe-cel) in up to 30 children with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The therapy uses the child's own immune cells, which are…

This study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…

This phase 3 trial is testing a CAR-T cell therapy called tisagenlecleucel that didn't quite meet commercial release standards. It's for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma who have no other approved options. The study will check if th…

This study tests a new type of CAR-T cell therapy, called UCD19 CAR-T, in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) or B-cell non-Hodgkin lymphoma (B-NHL) that has come back or not responded to standard treatment. The therapy is made locally to sp…

This phase II trial is testing a combination of two targeted drugs, inotuzumab ozogamicin and blinatumomab, with or without ponatinib, for adults with a type of leukemia called B-ALL. The study includes newly diagnosed older adults and those whose cancer has returned or not respo…

This early-phase trial is testing a new type of CAR T cell therapy called Azer-cel, which is made from healthy donor cells rather than the patient's own cells. It aims to treat adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and relat…

This early-stage trial tests a new drug called LY4152199 in about 215 adults with certain types of blood cancer (like follicular lymphoma or diffuse large B-cell lymphoma) that have already been treated. The drug is designed to help the body's immune cells attack the cancer. The …

This study tests a drug called glofitamab, which helps the immune system find and kill cancer cells, in children and young adults (ages 6 months to under 30) whose B-cell lymphoma has come back or not responded to treatment. Some participants receive glofitamab alone, while other…

This phase III trial is testing whether adding inotuzumab ozogamicin—a drug that targets cancer cells—to standard chemotherapy can improve outcomes for young adults (ages 18-39) newly diagnosed with B-cell acute lymphoblastic leukemia. About 310 participants will be enrolled. The…

This phase 2 trial is testing whether adding nivolumab to blinatumomab helps children and young adults (ages 1 to 30) with relapsed B-cell acute lymphoblastic leukemia (B-ALL), including those with Down syndrome. Blinatumomab helps the immune system find and kill cancer cells, wh…

This phase 3 trial tests whether adding the targeted drug inotuzumab ozogamicin to standard chemotherapy and immunotherapy improves outcomes for children and young adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The study will enroll about 6,000 participants an…

This early-stage trial tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have aggressive B-cell non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of…

This trial tests whether a personalized diet and exercise plan during the first month of chemotherapy can make leukemia cells more sensitive to treatment in older children, adolescents, and young adults with B-cell acute lymphoblastic leukemia (B-ALL). The study also aims to redu…

This study tests an experimental drug called AZD0486 in adolescents and adults whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to at least two prior treatments. The trial has three parts: first, finding a safe dose; second, optimizing that dose; an…

This study tests a CAR T-cell drug called brexucabtagene autoleucel in 40 adults with B-cell acute lymphocytic leukemia that has come back or is hard to treat. Participants first receive standard chemotherapy drugs to reduce cancer, then get the CAR T-cells. The goal is to see if…

This phase II trial is testing a combination of six chemotherapy drugs (clofarabine, etoposide, cyclophosphamide, liposomal vincristine, dexamethasone, and bortezomib) in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, or related cancers that have come back or…

This early-phase trial tests the safety of a new drug called karonudib in up to 9 adults with blood cancers like leukemia who have no standard treatment options left. The study aims to find a safe dose and look for any signs that the drug works. It is too early to know if karonud…

This early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…

This early-phase study tests a new treatment for adults with certain types of blood cancer (like lymphoma) that have come back or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (CAR T-cells) desig…

This early-phase trial tests a drug called pidnarulex (CX-5461) in about 50 people with aggressive B-cell lymphomas that have not responded to standard treatments. The goal is to find the best dose and check if the drug is safe and can shrink tumors. Participants will also have b…

This study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …

This early-phase study tests a new treatment called JV-213 for adults with B-cell lymphoma that has come back or not responded to other treatments. JV-213 uses the patient's own immune cells, modified to attack cancer cells. The main goal is to find the safest dose and monitor si…

This early-phase study is testing a new cell therapy called GT801 in 28 adults with relapsed or hard-to-treat B-cell blood cancers (like leukemia and lymphoma) or autoimmune hemolytic anemia (AIHA). The therapy uses a patient's own immune cells, modified to attack CD19-positive c…

This early-phase study is testing a new drug called YK012 in 48 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. YK012 is a bispecific antibody designed to help the body's immune T cells recognize and kill cancer B cells. The main goals are to check the drug's safe…

This early-phase trial tests whether the drug pomalidomide can improve the effects of CAR T-cell therapy in people with B-cell leukemias or lymphomas that have returned or not responded to treatment. The study will enroll 12 adults who have already received CAR T-cell therapy. Re…

This study is testing a drug called inotuzumab ozogamicin, which is like a smart bomb that targets and kills leukemia cells, combined with low-intensity chemotherapy. The goal is to find the best dose and see if this combo works better than standard treatments for patients with a…

This early-phase trial tests whether combining three drugs (recombinant Erwinia asparaginase, venetoclax, and blinatumomab) is safe and effective for adults whose B-cell acute lymphoblastic leukemia has returned or not responded to prior treatment. The study enrolls 26 people age…

This study tests a new drug called AZD4512 for people with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. The drug is an antibody-drug conjugate that delivers a toxic payload directly to cancer cells. The trial has two parts: first, f…

This study tests whether giving children with leukemia a special type of donor immune cell (CD45RA-depleted) after a stem cell transplant can help their immune system recover faster and lower the risk of serious viral or fungal infections. The trial enrolls 50 children under 25 w…

This study tests a stem cell transplant using a reduced-intensity conditioning regimen (lower doses of chemotherapy and radiation) followed by a donor stem cell infusion. The goal is to treat various blood cancers and blood disorders while lowering the risk of graft-versus-host d…

This study tests a combination of chemotherapy drugs (DA-EPOCH) plus an enzyme called asparaginase (Rylaze) in adults newly diagnosed with a fast-growing blood cancer (Philadelphia chromosome-negative ALL). The goal is to see if this mix can kill more cancer cells and achieve dee…

This study tests a new type of immunotherapy called CD22/CD19 dual-target CAR-T cells in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already achieved their first remission after standard treatment. The goal is to see if this therapy can safely and e…

This Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…

This early-phase trial is testing a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. It is for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. The main go…

This study tests a new immune cell therapy (dual-target CD22/CD19 CAR-T cells) as a consolidation treatment for people with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) who are in remission. The goal is to see if it is safe and can help prevent the cancer from coming…

This study is testing whether adding the drug rituximab early and intensively to a strong chemotherapy regimen can improve outcomes for children and teens with aggressive B-cell non-Hodgkin lymphoma. About 87 participants will receive the combination therapy. The goal is to see i…

This early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …

This study tests a stem cell transplant from half-matched (haploidentical) donors for people with various blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare their body. The goal is to replace diseased bone marrow with healthy don…

This study is testing a new version of CAR T-cell therapy for children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to target cancer cells. The trial aims to …

This phase II trial is testing whether adding two immunotherapy drugs (blinatumomab and inotuzumab ozogamicin) to a standard chemotherapy regimen (Hyper-CVAD) can improve outcomes for adults newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). The study plans to enro…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD19 and CD22, on leukemia cells. It is for children and young adults up to age 21 whose leukemia has returned or not responded to standard treatments. The main goal is to find…

This pilot study tests a stem cell transplant method that removes specific immune cells (alpha/beta T cells and B cells) from the donor cells before transplant. The goal is to reduce the risk of graft-versus-host disease, a serious complication, while still allowing the transplan…

This early-stage trial tests a new treatment called DuoCAR20.19.22-D95 for adults with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in the lab to better recognize and attack…

This phase 2 trial is testing a new type of CAR-T cell therapy called MB-CART2019.1 in children and teens (ages 6 months to under 18) with B-cell cancers that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to atta…

This phase 2 trial is testing a new treatment strategy for adults newly diagnosed with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). The approach combines a reduced-dose chemotherapy with a full course of the immunotherapy drug blinatumomab, and may a…

This phase 2 trial tests whether adding epcoritamab, a bispecific antibody that helps the immune system attack cancer cells, to standard chemotherapy (EPOCH-R) is safe and effective for aggressive B-cell non-Hodgkin lymphoma. About 18 patients with hard-to-treat forms of the dise…

This early-phase study tests a new treatment called CT1182 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. About 24 participants will receive the treatment to see if it is safe and how well it works. The goal is to find the bes…

This study is testing whether a drug called polatuzumab vedotin can safely help control lymphoma after a stem cell transplant. About 20 people with B-cell or Hodgkin lymphoma who have had a relapse or not responded to prior treatment will receive the drug if their disease is stab…

This study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Pa…

This study tests a personalized CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. Patients' own immune cells are collected, modified to target cancer cells, and infused back. The trial has two phases: first to find the safest dos…

This early-stage trial tests a new treatment called CLIC-2201 for people with B-cell cancers (like certain leukemias and lymphomas) that have come back or not responded to standard care. The treatment involves collecting a patient's own immune cells, modifying them to target a pr…

This phase 2 trial tests KTE-X19 (Tecartus), a personalized CAR T-cell therapy, in adults with B-cell acute lymphoblastic leukemia who are in remission but still have tiny amounts of cancer cells (minimal residual disease). The goal is to see if this treatment can clear those lef…

This study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…

This early-phase trial is testing a new version of CAR T-cell therapy that has been modified to improve its energy use, potentially making the cells more effective. It is for adults with certain types of B-cell lymphoma or chronic lymphocytic leukemia that have come back or not r…

This study tests a new approach for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. It combines two types of engineered immune cells (CAR T cells) that target different markers on cancer cells (CD19 and …

This study tests whether a new form of the drug asparaginase (made from a different bacterium) can be safely combined with standard chemotherapy for high-risk adults aged 18–54 with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma. The treatment aims to kill…

This study tests two approaches for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. One group gets a sequence of two types of CAR T-cells (targeting CD19 and CD22), while the other gets one type of CAR T-cell followed by a stem ce…

This early-phase trial tests a two-step approach for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. First, patients receive donor-derived CD19 CAR T cells, then a stem cell transplant from the same donor, followed by donor-derive…

This early-phase study is testing an experimental cell therapy called EBV-AST for people with Epstein-Barr virus (EBV)-related lymphoproliferative disorders, including certain blood cancers and post-transplant complications. About 18 adults will receive up to 3 infusions of the t…

This early-stage trial tests a new type of CAR T-cell therapy (CMD63) in 16 children whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The therapy uses specially engineered immune cells to target and kill cancer cells. The main goal i…

This study involves 1,000 children with Burkitt's lymphoma, a fast-growing cancer. Researchers want to see if checking children earlier and adjusting treatment based on response can improve outcomes, especially for advanced-stage disease. The goal is to refine treatment recommend…

This expanded access program provides an experimental CAR-T cell therapy called obe-cel to adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) who have no other treatment options. The therapy is made from the patient's own blood cells but did not meet com…

This early-phase study tests SYNCAR-100, a type of cell therapy (CAR-T), in 16 adults with CD19-positive B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. Participants receive four weekly injections, then are followed for safety and tu…

This study tests whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 213 participants will be randomly assigned to receive eith…

This early-phase trial tests whether a combination of three drugs—inotuzumab ozogamicin, venetoclax, and dexamethasone (IoVeX)—is safe for children and adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL). About 28 participants will receive the drugs over one or two 2…

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…

This early-stage trial is testing a new drug called YK012 in 46 people with B-cell acute lymphoblastic leukemia (B-ALL). The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of fighting the cancer. Participants will receive YK012 throu…

This study tests a new type of CAR-T cell therapy that uses mRNA to target two proteins (CD19 and CD20) on cancer cells. It is for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The goal is to see if it is safe and effective, with up to …

This early study is testing a new treatment called JY231 for people with B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. The main goal is to check if JY231 is safe and tolerable, and to see if it can help control the disease. About 20 adults and children up t…

This study tests whether adding two antibody drugs (mosunetuzumab and polatuzumab) after standard CAR-T cell therapy can improve tumor shrinkage in people with aggressive non-Hodgkin lymphoma that has relapsed or not responded to prior treatments. About 22 adults will receive the…

This early-stage trial is testing a one-time infusion of specially engineered immune cells from a healthy donor in 24 children and young adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The main goal is to check safety and find the…

This study tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) on leukemia cells. It is for children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard treatments. The main goal is to find a safe dose and see if the t…

This early-phase study tests a new type of CAR T-cell therapy for adults with blood cancers like leukemia, lymphoma, and multiple myeloma that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack canc…

This early-phase trial tests a two-step treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot have a standard donor stem cell transplant. First, patients receive the drug blinatumomab to clear any remaining cancer cells, then they undergo their own stem…

This study tests an oral drug called HQP1351 in people with chronic myeloid leukemia (CML) or a type of acute lymphoblastic leukemia (Ph+ ALL) that has not responded to at least two other treatments. The goal is to find the right dose and see how safe and effective the drug is. A…

This early-phase trial is testing a new drug called ABL001 together with three other medicines (dasatinib, prednisone, and blinatumomab) in people with BCR-ABL positive B-cell acute lymphoblastic leukemia or chronic myeloid leukemia in blast crisis. The study aims to find the saf…

This study is testing a new treatment called UCART22 for people with a type of blood cancer called B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. UCART22 uses donor immune cells that are engineered in a lab to recognize and attack …

This study looks at whether giving blood transfusions only when hemoglobin drops below 7 gm/dL (instead of 9 gm/dL) is safe and maintains quality of life in leukemia patients after chemotherapy or stem cell transplant. About 50 adults with certain blood cancers will be randomly a…

This study is a large registry that will collect medical information and biological samples from up to 10,000 adults with acute lymphoblastic leukemia (ALL) and related blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time. By gather…

This study is a registry that collects data from 200 adults with B-cell acute lymphoblastic leukemia who received blinatumomab as part of their treatment outside of a clinical trial. Researchers will look at how many patients achieve complete remission and overall survival. The g…

This study follows 500 people in South Korea who have received tisagenlecleucel, a CAR-T cell therapy, for certain blood cancers like acute lymphoblastic leukemia and lymphomas. Researchers will monitor side effects, risk of new cancers, and how well the treatment works over time…

This research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…

This study follows 80 children and young adults who received CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL) at least two years ago. Researchers want to see how feasible it is to track their long-term health, including any new or lasting side effects, brain fun…

This study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the immunotherapy drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus,…

This study follows 500 people who received CAR-T cells in earlier trials for blood cancers like lymphoma and multiple myeloma. Researchers will check for new cancers and track long-term safety and effectiveness over 15 years. No new treatment is given; it is purely an observation…

This study collects blood, tissue, and body fluid samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central lab for future research on diagnosis, prognosis, and immune monitoring. Participants do not receive any treatment as par…